Pharmaceutical and biotech stocks often are seen as steady and safe options for investors for one particular reason. Patients need their medications, so regardless of the economic environment, these companies generally see at least stability in revenue. But it's important to note that you can turn to these players for growth too.Drugmakers often see phases of growth as they develop candidates for a high-potential treatment area or as they launch promising new products. Over time, you can benefit from these ...

With a market capitalization of more than $143 billion today, Pfizer (PFE 0.83%) stock won't make anyone into a millionaire unless they're willing to commit a large amount of capital and then hold the stock for a very long period of time, reinvesting all the dividends they receive along the way. Big pharma businesses simply don't grow quickly enough to deliver investors the massive returns that are necessary to generate millions from a humble starting sum.There's no evidence that Pfizer is about to change i ...

Pfizer (PFE) closed the latest trading day at $25.23, indicating a -1.33% change from the previous session's end. The stock's change was less than the S&P 500's daily gain of 0.82%. Meanwhile, the Dow lost 0.22%, and the Nasdaq, a tech-heavy index, added 1.77%.The the stock of drugmaker has fallen by 2.37% in the past month, leading the Medical sector's loss of 4.06% and undershooting the S&P 500's gain of 0.8%.Analysts and investors alike will be keeping a close eye on the performance of Pfizer in its upco ...

Retirement is complicated and you only get once chance to do it right. Don't miss out because you didn't know what was out there.The Retirement Forum provides actionable ideals, a high-yield safe retirement portfolio, and macroeconomic outlooks, all to help you maximize your capital and your income. We search the entire market to help you maximize returns.Pfizer (NYSE: PFE ) is one of the largest pharmaceutical companies in the world. However, its share price has continued to struggle since our last recomme ...

Now you can get access to the latest and highest-quality analysis of recent Wall Street buying and selling ideas with just one subscription to Beyond the Wall Investing ! There is a free trial and a special discount of 10% for you. Join us today!I reinitiated my coverage of Pfizer Inc. (NYSE: PFE ) (NEOE: PFE:CA ) stock at the end of December 2023 with a "Buy" rating, when the stock was trading at $27.86 apiece. Since then, I have published 4 more bullishDaniel Sereda is chief investment analyst at a family ...

Pfizer's (PFE) stock has declined 7.8% in the past month. Though the stock has been affected by declining sales of its COVID products, a lot of this stock price decline could be due to the broader drug/biotech sector's decline in the past month. Lower-than-expected sales of Lilly (LLY) and Novo Nordisk's (NVO) popular diabetes and obesity drugs in the third quarter, guidance cuts, pipeline setbacks and the appointment of Robert F. Kennedy Jr., a vaccine skeptic, as head of Health and Human Services (HHS) ha ...

Things aren't getting much better for Pfizer (PFE -1.29%). The company is still suffering from the significant drop in sales of its coronavirus products and the less-than-impressive financial results it has produced during the past two years. And although Pfizer's revenue is growing again, that's not enough for the drugmaker to get back in the good graces of investors. Pfizer has, unquestionably, made progress. Many new approvals and acquisitions have expanded its lineup and pipeline. However, it's fair to ...

CHONGQING, CHINA - OCTOBER 27: The Pfizer logo is displayed on a smartphone screen in front of a ... [+] larger Pfizer logo on October 27, 2024 in Chongqing, China. (Photo by Cheng Xin/Getty Images) Getty Images Pfizer stock (NYSE: PFE) is down 7% in a month, amid rising concerns over the future of vaccines under Robert F. Kennedy Jr. in the new government, given the perception of him being a prominent anti-vaccine activist. Pfizer has had its own issues with falling Covid-19 vaccine sales weighing on its s ...

Goldman Sachs hosted a meeting with Pfizer Inc's PFE newly appointed Chief Scientific Officer Chris Boshoff (effective January 1, 2025). The analyst maintains the Buy rating with a price target of $33. When discussing core capabilities at Pfizer, the commentary highlighted a strategic shift toward prioritizing efforts. The focus will be on opportunities expected to deliver the highest economic returns while maintaining a balanced portfolio of high-risk and low-risk projects. With an annual R&D budget of abo ...

Despite Pfizer's (PFE 0.23%) recent struggles with falling earnings and a bid by an activist investor to unseat its leadership, the pharma juggernaut is still actively advancing its core priorities and giving investors plenty of reasons to consider buying its stock while it's cheap. With that in mind, here's one new initiative that's worth thinking about if you're wondering about whether to make an investment. This new play could lead to super-effective medicines down the line On Nov. 20, Pfizer announced t ...